{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:06Z","timestamp":1790880666663,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu\/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies. We hypothesized that combining these two promising approaches in a multi-institutional study of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates of severe acute and chronic GVHD, low toxicity, and effective disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Ninety-two adult patients (median age, 49 years; range, 21 to 65 years) with high-risk hematologic malignancies were enrolled at three centers (clinical trial No. NCT00809276). Forty-five patients received related allografts, and 47 received unrelated allografts. GVHD prophylaxis was solely with PTCy at 50 mg\/kg\/day on post-transplantation days +3 and +4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cumulative incidences of grades 2 to 4 acute, grades 3 to 4 acute, and chronic GVHD were 51%, 15%, and 14%, respectively. Nonrelapse mortality (NRM) at 100 days and 1 year were 9% and 16%, respectively. With a median follow-up period of 2.2 years, the 2-year disease-free survival (DFS) and overall survival (OS) rates were 62% and 67%, respectively. Donor relatedness did not affect NRM, DFS, or OS. Patients in complete remission (CR) without evidence of minimal residual disease (MRD) had markedly better DFS (80%) and OS (80%) than patients in CR with MRD or with active disease at the time of transplantation (DFS, P = .0005; OS, P = .019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multi-institutional study demonstrates that PTCy can be safely and effectively combined with IV Bu\/Flu myeloablative conditioning and confirms PTCy's efficacy as single-agent, short-course GVHD prophylaxis for both acute and chronic GVHD after bone marrow transplantation from HLA-matched donors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2013.54.0625","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T23:18:40Z","timestamp":1412032720000},"page":"3497-3505","source":"Crossref","is-referenced-by-count":264,"title":["Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning"],"prefix":"10.1200","volume":"32","author":[{"given":"Christopher G.","family":"Kanakry","sequence":"first","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Furlong","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos J.","family":"de Lima","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Medeot","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[{"name":"Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328342b82a"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203517"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0048"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396275"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.7.1423.1423"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12374451"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0414"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.009"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.007"},{"key":"B10","first-page":"56","volume":"2013","author":"Van Besien K","year":"2013","journal-title":"Am Soc Hematol Ed Book"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.09.005"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12171484"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251595"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241020-00002"},{"key":"B18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/em.20603","volume":"51","author":"Valdez BC","year":"2010","journal-title":"Environ Mol Mutagen"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.09.027"},{"key":"B20","first-page":"825","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0254"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"B25","first-page":"3671","volume":"96","author":"Cheson BD","year":"2000","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"B30","first-page":"163","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"B31","volume-title":"Bayesian Data Analysis (ed 2)","author":"Gelman A","year":"2004"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344136"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.01.017"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.353"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.011"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.4058.bloodjournal88104058"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.07.013"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.014"},{"key":"B41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1399-0012.1987.tb00685.x","volume":"1","author":"Santos GW","year":"1987","journal-title":"Clin Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006960"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0952"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.7071"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329821"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3523"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.06.009"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705770"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2362"},{"key":"B51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-6-15","volume":"6","author":"Liu H","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2010.04.004","volume":"16","author":"Pavletic SZ","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.10.008"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506725"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2013.54.0625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T18:39:45Z","timestamp":1746383985000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2013.54.0625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":54,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2014,11,1]]}},"alternative-id":["10.1200\/JCO.2013.54.0625"],"URL":"https:\/\/doi.org\/10.1200\/jco.2013.54.0625","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,1]]}}}